Implanon Nxt (Etonogestrel)

Etonogestrel released from the implant suppresses the hypothalamic‑pituitary‑ovarian axis, preventing the surge of luteinising hormone that triggers ovulation. In addition, it thickens cervical mucus and modifies the endometrial lining, creating multiple barriers that reduce the chance of fertilisation and implantation.

Implanon Nxt contains a fixed 68 mg dose of etonogestrel delivered continuously from a single subcutaneous rod. The prescribing clinician determines whether the implant is appropriate for the individual patient; no separate dosing schedule is required after insertion.

Implanon Nxt must not be inserted in a woman who is already pregnant, and it is intended for use before conception. If pregnancy occurs after insertion, the implant should be removed. Limited data are available on breastfeeding; clinicians usually consider the benefits and risks before recommending use in lactating women.

To place an order, submit an enquiry on the Implanon Nxt product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any required import documentation.

Implanon Nxt offers a three‑year duration of action from a single insertion, which is longer than most hormonal pills, patches or rings and comparable to other progestin implants such as Nexplanon. Unlike intra‑uterine devices, it does not require uterine placement, but both methods provide high efficacy and reversible contraception.

Implanon Nxt should be stored at ambient temperature, below 25 °C, in its original sealed packaging. Protect the product from moisture, direct sunlight and extreme temperatures to maintain the integrity of the implant until it is administered by a qualified healthcare professional.

A trained healthcare provider inserts the 68 mg etonogestrel rod subcutaneously into the inner side of the upper arm using a sterile applicator. The procedure takes only a few minutes, after which the implant remains in place and releases hormone continuously for up to three years.

Serious adverse events, although rare, include ectopic pregnancy, severe allergic reactions such as anaphylaxis, thromboembolic disorders, and significant hepatic dysfunction. Patients should be instructed to seek immediate medical attention if they experience symptoms suggestive of these conditions.

Implanon Nxt is contraindicated in women who are pregnant, have known or suspected breast cancer, active liver disease, unexplained vaginal bleeding, or a history of thromboembolic disorders. It should also be avoided in individuals with hypersensitivity to etonogestrel or any component of the implant.